About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Evaluation of a New Treatment for Migraine Attacks

NCT01880671·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Karolinska University Hospital

Age

20–55

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Female or male subjects, in otherwise good health, 20 to 55 years of age
Subjects who meet the ICHD-2 (2nd Edition of The International Headache Classification) criteria for migraine headache
Subjects with a minimum of 1 migraine attack per month
Attack duration of 4 to 72 hours
Normal attack intensity of at least 4 on a 0-10 VAS-scale

You may not be if

Completed heart surgery
Cardiovascular disease
Vascular damage on neck vessels
Disease other than migraine of the CSN
Severe disease of vital body organs
Severe psychiatric disorders
More than 6 migraine attacks per month

The record

StatusCompleted

PhaseNo phase

Taking part36

StartedMay 2013

UpdatedApr 1, 2014

Conditions

Where1

Karolinska University Hospital, Huddinge
Stockholm, Sweden

Clareo Health | Evaluation of a New Treatment for Migraine Attacks